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Abstract
Burkholderia cepacia complex (Bcc) is an opportunistic bacterial pathogen that causes chronic infections in people
with cystic fibrosis (CF). It is a highly antibiotic resistant organism and Bcc infections are rarely cleared from patients,
once they are colonized. The two most clinically relevant species within Bcc are Burkholderia cenocepacia and
Burkholderia multivorans. The virulence of these pathogens has not been fully elucidated and the virulence proteins
expressed during human infection have not been identified to date. Furthermore, given its antibiotic resistance,
prevention of infection with a prophylactic vaccine may represent a better alternative than eradication of an existing
infection. We have compared the immunoproteome of two strains each from these two species of Bcc, with the aim of
identifying immunogenic proteins which are common to both species. Fourteen immunoreactive proteins were
exclusive to both B. cenocepacia strains, while 15 were exclusive to B. multivorans. A total of 15 proteins were
immunogenic across both species. DNA-directed RNA polymerase, GroEL, 38kDa porin and elongation factor-Tu
were immunoreactive proteins expressed by all four strains examined. Many proteins which were immunoreactive in
both species, warrant further investigations in order to aid in the elucidation of the mechanisms of pathogenesis of
this difficult organism. In addition, identification of some of these could also allow the development of protective
vaccines which may prevent colonisation.
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Introduction
Burkholderia cepacia complex (Bcc) is a heterogenous group
of Gram negative bacteria comprising at least 17 species. It is
one of a number of opportunistic pathogens that causes
chronic respiratory infections in people with the genetically
inherited diseases cystic fibrosis (CF) and chronic
granulomatous disease (CGD). In contrast to other pathogens
associated with CF, such as Pseudomonas aeruginosa, a
subgroup of Bcc colonised patients can develop a fatal
necrotizing pneumonia associated with septicaemia referred to
as “cepacia syndrome” [1]. Bcc is particularly difficult to treat
due to its inherent antimicrobial resistance and once acquired it
is rarely eradicated. There are two species that are of particular
interest, Burkholderia cenocepacia which is the most virulent
species and Burkholderia multivorans, which is currently the
most frequently isolated Bcc species from newly colonised CF
patients [2,3]. Together these species account for 85% to 95%
of Bcc CF infections. Bcc are typically found in water and soil
and can survive for prolonged periods in moist environments
[4]. Although Bcc has been associated with patient-to-patient
transmission, these have now been largely minimised by strict
segregation measures [5]. The majority of new acquisitions of
B. multivorans are considered to be from the environment [4].
We and others have shown that environmental Bcc strains
have the potential to be as virulent as clinical strains [6,7].
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The mechanisms of colonisation and pathogenesis of Bcc
are still poorly understood [8] and many virulence factors
remain unidentified. In particular, the virulence factors
expressed by this pathogen during human infection have not
been elucidated to date. Well known virulence factors are
generally strongly immunogenic (for example, Streptococcus
pneumonia antigens [9]), therefore a key objective of this study
to identify novel Bcc virulence factors that might contribute to
the pathogenesis of this organism, using an immunoproteomics
approach with patient serum. Membrane proteins were of
particular interest as these are exposed to, and make direct
contact with, host cells and are therefore among the primary
antigen targets of the host immune system. In addition, another
aim of this study was to identify immunogenic proteins from
both B. multivorans and B. cenocepacia strains, which would
allow the development of protective vaccine antigens to
prevent colonisation by both the most commonly acquired
species and the most virulent species. Recent developments in
proteomics have allowed the analysis and identification of the
immunogenic proteins from pathogenic microbes, which has
led to the identification of novel antigens in many pathogenic
organisms such as Burkholderia pseudomallei, Pseudomonas
aeruginosa, Streptococcus pneumonia, Staphylococcus
epidermidis, and Neisseria meningitides [10-14] some of which
show promise as potential vaccine targets [15]. Given the high
levels of multidrug resistance within Bcc, prevention of
colonisation via vaccination may be a more promising
approach than eradication of a chronic infection.
We have examined membrane protein preparations from four
different Bcc strains from the International Burkholderia
cepacia Working Group panel [16] in order to focus on proteins
that are conserved across both species. These four strains
represent a piliated strain and non-piliated strain from B.
cenocepacia, BC-7 and C1394, respectively, and two strains
from B. multivorans, LMG 13010 and C1962.
Materials and Methods
Bacterial strains and culture conditions
The four bacterial strains used in this study, two B.
multivorans strains, LMG13010 and C1962, and two B.
cenocepacia strains, BC-7 (rec IIIA lineage) and C1394 (rec
IIIB lineage) and were obtained from the BCCM/LMG,
University of Ghent, Belgium and routinely plated on B. cepacia
specific agar (BCSA) [17]. The bacterial strains were routinely
cultured in Luria Bertani (LB) broth at 37°C with orbital shaking
(150 rpm). The stationary phase cultures were prepared in 10 L
fermenter for the isolation of membrane proteins at 37°C
without pH control or anti-foam control with an air supply of 6 L/
min.
Membrane protein preparation
Membrane proteins from B. multivorans strain LMG13010
and C1962 or B. cenocepacia strain BC-7 and C1394 were
prepared by centrifugation of cells at 5,000 g for 10 min at 4 °C,
and resuspended in ice cold PBS containing 5 % CHAPS 3-[(3-
cholamidopropyl) dimethyl ammonio]-1-propane sulfonate) and
protease inhibitor cocktail. Cell debris was removed 5,000 g for
10 min at 4° C, the supernatants ultracentrifuged at 30,000 g at
4 °C for 30 min and the pellets were resuspended in 10 mL of 2
mM MgCl2, 50 mM Tris (pH 8) containing protease inhibitor
cocktail and centrifuged under the same conditions. The new
pellets were resuspended in 2 % Triton X-100, 50 mM Tris (pH
8) with protease inhibitor cocktail and incubated for 30 min at
40 °C with gentle shaking. The ultracentrifugation was repeated
for another hour, the pellets were washed with 50 mM Tris
(pH8) buffer with protease inhibitors and ultracentrifuged in the
same conditions. The final pellets were resuspended in 50 mM
Tris, pH 8 and analysed for protein content using Bradford
assay. Membrane preparations were prepared on three
independent occasions for each strain.
Protein Separation by 2-D gel Electrophoresis
The membrane protein preparations were solubilised for
isoelectric focusing (IEF) in rehydration solution (8 M urea, 2 M
thiourea, 4 % CHAPS, 1 % Triton, 10 mM Tris base, 65 mM
dithiothreitol (DTT) and 0.8 % (v/v) IPG buffer (pH 3-11) and a
trace of bromophenol blue. The Immobilised pH gradient strips
non-linear (IPG) strips (pH 3-11NL) of 7 cm were rehydrated
overnight with 120 μL of the rehydration solution containing 120
µg of proteins. The IEF step was carried out for 3 h focusing
with a total voltage of 7,000V applied and the IPG strips
equilibrated in reducing buffer for 20 min under agitation in 30
% glycerol, 2 % sodium dodecyl sulphate (SDS), 6 M urea, 50
mM Tris and 2 % DTT. The IPG strips were then alkylated in
the same buffer containing 2.5 % iodoacetamide. The IPG
strips were placed on 12 % SDS-PAGE gels and the
separation was carried out at 110 V. For each individual
experiment, three gels were prepared, one of which was
stained with Coomassie blue (PageBlue, Fermentas) and the
other two were transferred to PVDF membrane for subsequent
immunoprobing. Blots were repeated on separate independent
membrane preparations for each individual strain.
Human sera samples
Sera from seven adult CF patients that had a history of Bcc
infection (Bcc+) were pooled to maximise the identification of
immunogenic proteins and avoid patient-specific effects. In
addition, serum from six adult CF patients that had no history of
Bcc infection and that were confirmed as negative for Bcc
infection was used as negative controls (Bcc-). These six Bcc
negative sera were positive for P. aeruginosa antibodies. All
subjects gave written informed consent to the use of their
serum. Ethics approval was obtained for working with sera from
CF patients from the St Vincent’s University Hospital Research
Ethics Committee and from the Institute of Technology Tallaght
Dublin Research and Ethics Committee.
Immunoblotting of bacterial membrane proteins
Prior to transfer of the proteins from gels to the PVDF
membrane, the gels were equilibrated in the transfer buffer (25
mM Tris, 192 mM glycine, 20 % (v/v) methanol) for 15 min and
protein transfer was performed in a semi-dry Transphor unit
(Bio-Rad) at 330 mA for 50 min. The PVDF membrane was
then blocked with 5 % BSA and 2 % Marvel® dried milk powder
in PBS overnight at 4° C. Pairs of blots were either probed with
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pooled Bcc+ serum or Bcc- serum, (1;8,000), for 1 h and
washed with PBST (0.05 % Tween-20) three times. The blots
were incubated with HRP conjugated secondary Ab (1:16,000,
Roche) and washed again five times with PBS containing 0.4
% Tween-20. Chemiluminescent detection was carried with
Ampli-Cruz detection kit (Santa Cruz Biotechnology, Germany)
and exposed to Kodak photographic film.
In gel trypsin digestion and MALDI-ToF MS/MS analysis
Protein spots excised from 2-D gels were destained with an
equal volume of 100 mM ammonium bicarbonate and
acetonitrile. Gel digestion was performed with 13 ng μL-1
modified porcine trypsin for 2 h on ice followed by overnight
incubation of samples at 37 °C. Tubes were chilled to RT, and
gel pieces pelleted using a micro-centrifuge. Aliquots of 2 to 2.5
μL of the supernatant were withdrawn directly from the digest
for MALDI-ToF MS/MS analysis with an Ultraflex MALDI-ToF
mass spectrometer (BrukerDaltonics), without further
extraction. An equal volume of peptide extracts and matrix
solution (2 mg mL-1 α-cyano-4-hydroxycinnamic acid (CHCA) in
70 % of 0.1 % TFA and 30 % of acetonitrile) were applied on to
the target plate along with peptide calibration standards and
BSA as a control and allowed to dry [18]. Peptide Mass
Fingerprinting (PMF) was used for protein identification and the
spectra were analysed in Flex Analysis and BioTools software
from BrukerDaltonics. Peak lists were submitted to the
MASCOT (http://www.matrixscience.com) search engine for
analysis. Protein sequence database searching was performed
on the NCBInr database. The general search parameters were:
monoisotopic molecular masses, all species, variable
modification was methionine oxidation and global modification
was carbamidomethyl cysteine alkylation, with a mass
tolerance of 100 ppm.
Identification of immunogenic membrane proteins from
B. cenocepacia and B. multivorans by Bcc infected CF
patient sera
The gels were manually aligned on the top of blots by using
chaperonin GroEL protein as standard marker as it was clearly
identified in all four strains. GroEL has molecular mass of 57
kDa and pI 5 was clearly detectable in blots probed with patient
sera. A second protein, porin (38 kDa, pI 9.5) was clearly
identified in Coomassie blue stained gels from all 4 strains.
Both of these proteins acted as a landmark proteins in the
analysis. The identified proteins had high sequence coverage
in mass spectrometric analysis (i.e. greater than 50% in the
majority of cases and the highest is 90%).
Results
Comparison of proteins from the two B. cenocepacia
strains, BC-7 and C1394
The two B. cenocepacia strains were selected as examples
of a piliated strain (BC-7) and non-piliated strain (C1394).
About 100 protein spots were separated on each gel (Figure 1),
among these 60 kDa chaperonin GroEL (spot 1 Figure 1A and
1B) and 38 kDa Porin (spot 23, Figures 1A and 18 in Figure
1B) showed a consistent pattern on both gels. Comparison of
the Coomassie blue images indicates that there were
considerable differences between the proteins isolated from
each of these two B. cenocepacia strains. In particular, thiolase
isozymes (Spots 13 & 14 Figure 1A) were clearly identified in
C1394 but were not readily detectable on the BC-7 gels. The
enzymes like inosine 5'-monophosphate dehydrogenase
(IMPDH) (Figure 1A, spot 8, 9, 10 and 11) and alcohol
dehydrogenase (spots 16,17 and 18) were also strongly
expressed in C1394 cells and were absent in BC-7. In addition,
outer membrane protein OprM (spots 2, 4, 5 Figure 1B) and
outer membrane protein A precursor (spot 23, Figure 1B) were
expressed in BC-7 cells, but were not visible on the C1394 gel
(Figure 1A).
Immunoblot analysis of B. cenocepacia membrane
proteins using CF patient serum
When the proteins of the B. cenocepacia strains were probed
with Bcc+ serum to identify the immunogenic proteins, an
abundance of proteins was apparent (Figure 1C and D). Over
forty different strongly immunogenic proteins were visible in
blots from both strains, 32 of which were identified by MALDI-
ToF MS (Table 1). The most immunoreactive proteins spanned
a broad range of pI values between 4.5 and 10 and molecular
mass from 20 to 60 kDa. There were approximately 12 proteins
with a pI value between 7 to 11 in the two B. cenocepacia
strains.
Nine spots were identified as immunoreactive in both strains,
including highly immunoreactive proteins such as DNA-directed
RNA polymerase subunit alpha corresponding to spots 19 and
20 in C1394 (Figure 1C) and spots 11 and 12 in BC-7 (Figure
1D). Chaperonin GroEL (spot 1 in both blots) and
phosphopyruvate hydratase (spot numbers 37 and 10 in C1394
and BC-7 blots, respectively) (Table 1) were also immunogenic
in both strains. The 38 kDa Porin (spot 18 in BC-7; 23 in
C1394), which was used as a landmark spot was weakly
immunogenic in both B. cenocepacia strains.
A considerable number of immunogenic proteins appeared to
be unique across all three experiments to an individual B.
cenocepacia strain, such as thiolase (spot 13), aldehyde
dehydrogenase (spot 5), IMPDH (spot 8, 9, 10, 11), and Zn-
dependent alcohol dehydrogenase were specific to the non-
piliated B. cenocepacia C1394 strain. In contrast, outer
membrane efflux protein OprA (spot 9) and ATP synthase F1
alpha subunit (spot 6) are examples of immunogenic proteins
which were identified on BC-7 immunoblots but not C1394
immunoblots (Table 1). These immunogenic proteins were
identified in duplicate samples taken from three independent
experiments. Certain protein spots on the gels were weakly
stained, in contrast to the clear and strong signals on
immunoblot, with the result that several immunogenic proteins
could not be identified. It is clear that these proteins generated
an abundance of antibodies in CF patient serum despite being
expressed at an apparently low level in the Bcc strains. The
subcellular localisation of the immunogenic proteins was
predicted using PSORTb V3 (http://www.psort.org)[19]. Of the
32 immunogenic proteins in Table 1, only 6 were predicted to
be outer membrane proteins (OMPs), while 2 were predicted to
Immunoproteomic Analysis of Bcc with CF Serum
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Figure 1.  Representative Coomassie blue stained 2-D gel (pI 3-11) of B. cenocepacia strains, C1394 (A) and BC-7 (B) and
the corresponding Western blots probed with pooled patient serum from Bcc colonised patients (C and D) or with serum
from patients with no history of Bcc colonisation (E and F).  Each gel was prepared with 120 µg membrane protein
preparations extracted from 18 h cultures grown at 37 °C, focused on IEF strips (pH 3 to pH 11) separated on 12% SDS-PAGE
gels, , blotted and probed the respective sera and detected with anti-human IgG. The corresponding spots on the gel were excised
and identified by MALDI-ToF/MS analysis. The numbers represent the proteins spots referred to in the text. The approximate
positions of molecular mass markers (kDa) are indicated.
doi: 10.1371/journal.pone.0080796.g001
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Table 1. Immunogenic proteins observed in B. cenocepacia strains as identified by 2-D gels and MALDI-ToF mass
spectrometry.
Protein name Functional category
Accession
Number   
Predicted
Subcellular
locationa
Localisation
score
MW(kDa) /
pIb   
Seq.
coverage
(%)   Scorec   Strain
alkyl hydroperoxide reductase/
Thiol specific antioxidant Cellular processes gi|107028881 CP 9.97 20.5/4.9 44-55 84-118
BC-7,
C1394
chaperonin GroEL Protein stabilisation gi|161525697 CP 9.97 57.1/5.0 46-66 200-217 BC-7,C1394
dipeptide transporter ATP-binding
subunit Transport and binding gi|107023972 CPM 7.88 37.5/9.5 26.3-42 63-107
BC-7,
C1394
divergent AAA domain protein Transcription gi|323143202 CP 8.96 57.1/7 21-27 86-92 BC-7,C1394
DNA-directed RNA polymerase
subunit alpha Transcription gi|161523455 CP 9.97 35.7/5.6 43-60 81-172
BC-7,
C1394
elongation factor Tu Transcription gi|78064909 gi|221213513 CP 9.97 43.1/5.3 27-61 52-113
BC-7,
C1394
phosphopyruvate hydratase Energy metabolism -glycolysis gi|134296288 CP 9.97 45.9/4.6 46-50 139-119
BC-7,
C1394
porin Transport and bindingprotein gi|107025986 OM 10.0 37.7/9.7 40-65 119-139
BC-7,
C1394
putative ubiquinone biosynthesis
protein UbiB Unknown function gi|161523750 CPM 7.88 59.9/9.3 21.7-22 66
BC-7,
C1394
30S ribosomal protein S1 Protein synthesis gi|161525427 CP 9.97 62.2/4.9 22-26 88-110 BC-7
Enoyl CoA hydratase Cell-cell communication gi|311104936 CP 9.97 29.8/4.8 32-34 102-121 BC-7
EvpB family type VI secretion
protein Secretion protein gi|161526098 CP 9.26 55.0/5.1 52-57 91-97 BC-7
F0F1 ATP synthase subunit alpha Energy metabolism -electron motive force gi|161523284 CP 9.97 55.8/5.5 32.7-62.1 96-185 BC-7
Hypothetical protein BCAS0292 Unknown function gi|197295141 U U 19.9/5.6 56-84 180-208 BC7
LysM domain/M23 peptidase
domain protein Peptidoglycan binding gi|221198090 OM 9.93 30.0/9.9 37-44 66-83 BC-7
OmpA/MotB domain-containing
protein OM protein gi|115350969 OM 9.93 24.1/10.1 55-56 105-328 BC-7
outer membrane efflux protein
OprA Transport and binding gi|221212959 OM 10.0 52.9/9.1 37-44 66-83 BC-7
outer membrane protein OprM Transport and binding gi|221200195 OM 10.0 54.3/5/7 36.9-43 112-524 BC-7
oxidoreductase, aldo/keto
reductase family Energy metabolism gi|221201924 CP 9.97 38.2/5.8 44-56.8 95-114 BC-7
Peptidoglycan-associated
lipoprotein Transport gi|357936457 OM 10.0 18.5/6.6 23-30 58 BC-7
Polyribonucleotide
nucleotidyltransferase
RNA binding and catabolic
processing gi|221211731 CP 9.97 77/5.2 24.9-28 94-111 BC-7
Putative ferritin DPS-family Binding
protein DNA binding gi|206561636 CP 9.26 18.0/5.7 46-56 100-124 BC-7
putative outer membrane porin Transport and bindingprotein gi|221196031 OM 10.0 38.0/9.5 39.0-49.9 109-685 BC-7
ubiquinone/menaquinone
biosynthesis methyltransferase Metabolic processes gi|107023667 CP 9.97 27.1/9.1 30-54 81-130 BC-7
acetyl-CoA acetyltransferase Metabolic processes gi|107023705 CP 9.97 40.5/6.7 19-51 100-273 C1394
Zn-dependent alcohol
dehydrogenase
Energy metabolism
glycolysis,
gluconeogenesis,
chloroalkane metabolism
gi|254248364 CP 9.97 38.2/6.3 52-57 102-204 C1394
Immunoproteomic Analysis of Bcc with CF Serum
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be on the cytoplasmic membrane. The remaining proteins were
predicted to be cytoplasmic or were predicted as “unknown”.
In comparison to the blots probed with Bcc+ serum, there
was a considerable difference in the number and level of
immunoreactive proteins in blots probed with Bcc- serum
(Figure 1E and 1F). Due to the high incidence of P. aeruginosa
colonisation among adult CF patients, all sera used in the
control blots were seropositive for P. aeruginosa. These
showed a much weaker antibody response, indicating that the
majority of immunogenic proteins in Bcc were not expressed by
P. aeruginosa or were not homologous to P. aeruginosa
proteins. Certain proteins were weakly cross-reactive, for
example, chaperonin GroEL, probably due to homology
between certain conserved P. aeruginosa antigens and Bcc
proteins. The low signal intensities on the immunoblots probed
with Bcc- serum confirm a high concentration of specific
antibodies are produced in serum specifically in response to
Bcc colonisation.
There were several immunogenic proteins present in both
blots at the low MW region (below 25kDa). These were not well
resolved on 12% gels but were identifiable using 15% gels
(Figure 2). Additional immunogenic proteins were identified on
these gels and blots. These include Enoyl coA-hydratase,
putative ferritin DPS family DNA binding protein, a hypothetical
protein product of gene BCAS0292 and ubiquinone/
menaquinone biosynthesis methyltransferase.
Comparison of protein expression in the two B.
multivorans strains
Approximately 100 distinguishable protein spots were
identified on the Coomassie blue stained 2-D gel of both C1962
and LMG13010 (Figure 3). There was more similarity between
the proteins of the two B. multivorans strains than there was
between the two B. cenocepacia strains. However, there were
certain proteins that were present in the LMG13010 gel and
absent in the C1962 gel and vice versa. For example,
transketolase and aminotransferase respectively, were strongly
expressed in C1962 gels but were not detectable in LMG13010
gels. The migration pattern of chaperonin GroEL (spot 6 and 7
in Figure 3A and spot 45 in Figure 3B) and 38kDa porin (spot
47 in Figure 3A and spot 24 and 25 in Figure 3B) were
comparable on all B. multivorans gels, consistent with the
observations in B. cenocepacia and again these were used to
align the gels and blots. Further similarity across the two
species was indicated by elongation factor Tu, acetyl-CoA
acetyltransferase and cell shape determining protein being
identified in B. cenocepacia and in B. multivorans.
Immunoblot analysis of B. multivorans membrane
proteins using CF patient serum
Immunoblotting of B. multivorans proteins also showed a
clear difference in pattern and intensity of immunogenic
proteins blots probed with Bcc+ serum (Figure 3C, 3D) relative
to those probed with Bcc- serum (Figure 3 E and 3F). Among
the 100 proteins identified on the Coomassie blue stained gels,
33 proteins were detected by CF patient serum antibodies and
showed strong signals on the immunoblot (Table 2). Seventeen
Table 1 (continued).
Protein name Functional category
Accession
Number   
Predicted
Subcellular
locationa
Localisation
score
MW(kDa) /
pIb   
Seq.
coverage
(%)   Scorec   Strain
aldehyde dehydrogenase
Energy metabolism /
glycolysis,
gluconeogenesis,
chloroalkane metabolism
gi|170737358 CP 9.97 54.2/5.8 20.5-34.2 71-102 C1394
cell shape determining protein,
mreb/mrl family Cell membrane gi|319761104 CP 9.97 37.0/5.1 24 82-94 C1394
F0F1 ATP synthase subunit beta
Energy metabolism - ATP-
proton motive force
interconversion
gi|107024491 CP 9.12 50.7/5.1 34-40 82-104 C1394
HAD family hydrolase Unknown function/ enzymeof unknown specificity gi|107022869 CP 9.97 24.5/5.3 48.8-57 66-101 C1394
hypothetical protein Bcen_2492 Hypothetical protein gi|107024037 CP 9.97 32.0/8.9 32-46 71-140 C1394
inosine 5'-monophosphate
dehydrogenase
Unknown function/ enzyme
of unknown specificity
gi|206560426  gi|
115352075 CP 9.97 52.2/7.1 32.3-51.4 80-150 C1394
Thiolase Unknown function/ enzymeof unknown specificity gi|254248092 CP 9.97 40.5/7.8 37.9-57.1 98-196 C1394
a Predicted subcellular localisation determined using PSORTb V3 (www.psort.org) [19]. OM: outer membrane; CPM: Cytoplasmic membrane; CP: cytoplasmic, U: unknown.
b Theoretical molecular mass (kDa) and isoelectric point were determined by Mascot.
c Ranges represent MS/MS ion scores determined by peptide mass fingerprinting [61]. Only scores which were deemed to be significant by Mascot (p<0.05) are reported.
doi: 10.1371/journal.pone.0080796.t001
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immunoreactive proteins were identified in both strains,
including proteins such as LysM domain/M23 peptidase, DNA
directed RNA polymerase and F0F1 ATP synthase. There were
five immunogenic proteins which were clearly observed on
LMG13010 blots (of 12% gels) and not observed in C1962
blots. In addition, three proteins that were reproducibly
identified on the C1962 blots were not identified on LMG 13010
blots. Further analysis of low molecular mass proteins on 15%
gels (Figure 4) allowed the identification of three additional
immunoreactive proteins, GTP cyclohydrolase, Hcp1 secretion
effector, hydroperoxide reductase and type VI secretion protein
(Table 2). As with B. cenocepacia, due to low abundance of
certain proteins on the gels, some immunoblot spots could not
be identified unambiguously in the 2-D gel of both strains.
Immunogenic proteins common to both species
DNA-directed RNA polymerase, GroEL, elongation factor Tu
and the 38 kDa porin were common to all four strains (Figure
5). Furthermore, there were a total of 15 immunoreactive
proteins which were common across both species and the
similarities have been compared in Table 3. In the case of
seven proteins, the accession number identified on MALDI was
the same one for both species, for example, for chaperonin
GroEL, the corresponding B. multivorans protein had the
highest score for all 4 strains by MASCOT. Six of the other 15
proteins had sequence identities which were 97% or greater
across the two species. The least similar protein among this
fourteen was porin; BLAST analysis revealed the identity was
only 79% [20]. The close similarity of these cross-reactive
antigens highlights the potential for these antigens as
protective antigens for both species.
Discussion
This study identified a wide range of proteins expressed by
the two most common Burkholderia species that colonise CF
patients during infection. Although an analysis of the
immunogenic proteins in the secretome of another member of
the Bcc, B. cepacia, has been reported [21], this species
represents only 2% of Bcc infection among CF patients [22].
Furthermore that study utilised mouse serum, rather than CF
patient serum. There has been no study to examine or identify
the membrane proteins expressed by any Bcc species during
human infection. In order to address this gap in our knowledge
we examined the immunoreactive proteins expressed in
membrane protein preparations from the two most clinically
relevant species of the Bcc, comparing four strains. Previous
immunoproteomic studies on P. aeruginosa and N. meningitidis
reported that there were striking differences in the antigens
recognised by sera from different patients [12,13]. We wanted
to get a global view of immunogenic proteins in both clinically
relevant species of Bcc and used pooled serum from Bcc-
colonised patients to avoid patient-specific effects. Stationary
phase cultures were used as this growth phase best resembles
the physiological state of bacteria which chronically colonise
the lung. Studies carried out using alternative culture conditions
that associated are also associated with the CF lung, including
low pH and hypoxia could well highlight additional
immunogenic proteins.
Figure 2.  Representative Coomassie blue stained 15% 2-D gels and corresponding blots for B. cenocepacia strain
BC-7.  Each gel was prepared with 120 µg membrane protein preparations extracted from 18 h stationary phase cultures, focussed
on pH gradient strips (pH 3 to pH 11), separated on 15% SDS PAGE gels and either stained with Coomassie blue (A) or probed
with serum from Bcc colonised CF patients (B). The approximate positions of molecular mass markers (kDa) are indicated beside
the Coomassie blue stained gel.
doi: 10.1371/journal.pone.0080796.g002
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Figure 3.  Representative Coomassie blue stained 2-D gel (pI 3-11) of B. multivorans strains, LMG13010 (A, E) and C1962
(B) and the corresponding Western blots probed with pooled patient serum from Bcc colonised patients (C and D) or with
serum from patients with no history of Bcc colonisation (E and F).  Each 12 % 2-D gel was prepared with membrane protein
preparations extracted from 18 h cultures grown at 37° , and focused on IEF strips (pH 3 to pH 11), blotted and probed the
respective sera and detected with anti-human IgG. The corresponding spots on the gel was excised and identified by MALDI-
ToF/MS analysis. The numbers represent the proteins spots referred to in the text. The images shown are representative of three
individual experiments.
doi: 10.1371/journal.pone.0080796.g003
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Figure 4.  Representative Coomassie blue stained 15% gels and corresponding blots for B. multivorans strain
LMG13010.  Each gel was prepared with 120 µg membrane protein preparations extracted from 18 h stationary phase cultures,
focussed on pH gradient strips (pH 3 to pH 11), separated on 15% SDS PAGE gels and either stained with Coomassie blue (A) or
probed with serum from Bcc colonised CF patients (B). The approximate positions of molecular mass markers (kDa) are indicated
beside the Coomassie blue stained gel.
doi: 10.1371/journal.pone.0080796.g004
Figure 5.  Venn diagram illustrating the numbers of immunogenic proteins identified which were common among strains
examined from each species analysed.  
doi: 10.1371/journal.pone.0080796.g005
Immunoproteomic Analysis of Bcc with CF Serum
PLOS ONE | www.plosone.org 10 November 2013 | Volume 8 | Issue 11 | e80796
This proteomic analysis has reproducibly identified 44
immunogenic proteins across both species. Among these
proteins, while 14 proteins (Table 3) were identified in both B.
multivorans and B. cenocepacia, the number of proteins
identified as immunogenic in all four strains examined was
surprisingly small: GroEL, 38kDa porin, DNA-directed RNA
polymerase (RNAP) and EF-Tu A total of 14 proteins were
exclusive to B. cenocepacia only, while 15 were identified in B.
multivorans only. Given inter-patient differences observed in
other immunoproteomic studies, all seven patients are unlikely
to produce antibodies against all four conserved proteins and
therefore more biological variability is likely. Considerable
differences in immunoreactive proteins were identified in the
two B. cenocepacia strains. These two strains, BC-7 and
C1394 represent different lineages within the B. cenocepacia
species, as determined by recA gene sequence and referred to
as IIIA and IIIB, respectively. This strongly suggests that a
multi-component vaccine would be needed to protect CF
patients from both B. multivorans and B. cenocepacia.
Vaccination studies against CF pathogens have
predominantly focussed on P. aeruginosa as it is the leading
cause of respiratory infections in the CF population. There
have been only two in vivo mouse vaccination studies reported
against Bcc, both of which involved unpurified membrane
proteins preparations. Bertot et al. described the protection of
mice against either B. cenocepacia or B. multivorans challenge
following nasal immunisation with an enriched membrane
proteins preparation administered with a mucosal adjuvant [23].
More recently mice were protected from B. cenocepacia using
enriched membrane proteins administered intranasally as a
nanoemulsion preparation [24]. Both studies demonstrate the
potential for membrane proteins as protective antigens, and
although the 17 kDa membrane protein was identified as an
immunodominant antigen in the latter study, identification of
any other antigens that elicited these protective responses and
may represent protective antigens for in a multi-subunit vaccine
formulation have not been elucidated to date [24].
RNAP was identified as immunoreactive in all four strains
examined. It has previously been shown to be immunogenic in
B. pertussis (BP642) and Chlamydia trachomatis [25]. The
RNAP alpha subunit (BCAL0260) was upregulated in B.
cenocepacia in response to low pH in recent studies [26]. It
was differentially altered in B. pertussis during iron starvation
and was suggested to be associated with virulence in that
organism [27]. Many virulence regulators have been shown to
interact directly with RNAP, including those in F. tularensis [28]
and Vibrio vulnificus [29]. RNAP may also contribute to the
activation of invasion genes in Salmonella enterica [30]. We
and others have shown that Bcc can invade human lung
epithelial cells [31,32] and immunogenicity of RNAP in CF
patients indicates that it could also play an active role in the
pathogenicity of Bcc, and may be involved in its intracellular
invasion.
Elongation factor Tu (EF-Tu) is the another immunogenic
protein which was common to all four strains. It was previously
identified as an immunoreactive protein in the secretome of
another Bcc species, B. cepacia [21]. Although membrane
proteins preparations were used in this study, it is clear that
many of the immunogenic proteins identified were predicted to
be cytosolic in cellular localisation. Riedel et al. first reported a
rigorous analysis of the proteome of a B. cenocepacia strain
and highlighted the overlap of proteins from distinct subcellular
Table 3. Immunogenic proteins shared between B. cenocepacia and B. multivorans and their sequence similarity.
Protein name Accession Number(s)
Subcellular
locationa   Localisation score   Identities (%)[62]   
chaperonin GroEL gi|161525697* CP 9.97 100%*
DNA-directed RNA polymerase subunit alpha gi|161523455* CP 9.97 100%*
elongation factor Tu gi|78064909 gi|221213513 CP 9.97 371/384 (97%)
F0F1 ATP synthase subunit alpha gi|161523284* CP 9.97 100%*
LysM domain/M23 peptidase domain protein gi|221212760 gi|221198090 OM 9.93 287/289 (99%)
OmpA/MotB domain-containing protein gi|161525435 gi|115350969 OM 9.93 221/222 (99%)
Outer membrane lipoprotein precursor Peptidoglycan-
associated lipoprotein gi|30314414 gi|357936457 OM 10 125/149 (84%)
outer membrane protein OprM gi|221200195* OM 10.0 100%*
oxidoreductase, aldo/keto reductase family gi|221201924* CP 9.97 100%*
porin gi|107025986 gi|161520486 gi|221196031 OM 10.0 292/368 (79%) (99%)
dipeptide transporter ATP-binding subunit gi|107023972* CPM 7.88 100%*
EvpB family type VI secretion protein gi|161526098* CP 9.26 100%*
Alkyl hydroperoxide reductase/ thiol specific reductase
Hydroperoxide reductase gi|107028881 gi|53719707 CP 9.97 179/182(98%)
phosphopyruvate hydratase gi|134296288 gi|161524338 CP 9.97 423/427 (99%)
Acetyl CoA Acetyltransferase gi|107023705 gi|221198056 CP 9.97 381/392(97%)
a Predicted subcellular localisation determined using PSORTb V3 (www.psort.org)[19] OM: outer membrane; CPM: Cytoplasmic membrane; CP: cytoplasmic; P:
Periplasmic; U: unknown
* Accession number identified was identical for all strains, therefore, 100% identity inevitable.
doi: 10.1371/journal.pone.0080796.t003
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locations [33]. Of the 304 intracellular proteins that they
identified, 46 were also located in either the extracellular or
surface fractions. EF-Tu was reported as being highly
abundant in B. cenocepacia and was present in all three
fractions examined (intra-, extra- cellular and surface) [33]. The
strong humoral responses of intracellular proteins among Bcc
colonised CF patients in our study, indicates that the host
immune system is exposed to these proteins either due to cell
death or secretion via membrane bound vesicles. It is likely that
the latter case is involved in the host recognition of EF-Tu,
since it was secreted in outer membrane vesicles of
Burkholderia pseudomallei [14]. It was also shown to reduce
lung bacterial loads following challenge with a related organism
B. thailandensis when used to immunise mice [14]. As with
RNAP, EF-Tu was also shown to be upregulated in B.
cenocepacia in response to low pH, but not low oxygen or low
iron, or nutrient deficient medium [26]. EF-Tu was also
immunoreactive in F. tularensis, Sh. flexineri, Bacillus anthracis
and P. aeruginosa and binds to host proteins, such as
fibrinogen and plasminogen [34-37]. Given that it was identified
in both B. multivorans and B. cenocepacia, the role of EF-Tu in
Bcc virulence warrants further investigation.
Chaperonin GroEL was also immunoreactive across all four
strains examined. It has been identified as immunogenic in
many species including Shigella flexineri, Yersinia
enterocolitica, B. pseudomallei and P. aeruginosa
[12,34,38,39]. This stress response protein has been shown to
be upregulated in leptospires cultured following in vivo infection
relative to those cultured in vitro [40]. It has been associated
with intracellular invasion of Legionella [41]. This well
conserved protein was protective against lethal S. pneumoniae
challenge [42] and conferred 100% protection against Bacillus
anthracis infection [43] in mice. Although GroEL is abundant in
all four Bcc strains examined, given its level of expression, it is
less immunogenic than many other immunoreactive proteins
identified and may not be relevant as a virulence factor nor be
a good vaccine candidate for this species.
Although 38 kDa porin (pI 9.5-9.7) served as a landmark
protein, it was also weakly immunogenic across all four strains
and consequently is not likely to represent either a major
virulence protein or a vaccine candidate in Bcc. Furthermore, it
was the protein with the lowest sequence similarity between B.
cenocepacia and B. multivorans, relative to the other 13
common proteins. Another porin, OprM was considerably
immunogenic, but was only identified in three strains. This 54.3
kDa porin is a component of the MexA-MexB-OprM efflux
system, which was found to mediate multidrug resistance in Ps.
aeruginosa [44].
A number of other immunoreactive Bcc proteins have been
previously associated with binding of other pathogens to host
proteins, including phosphopyruvate hydratase (Pph), which
was identified in three of the four strains. Pph, also known as
enolase, was immunogenic in other invasive organisms, such
as S. pneumoniae [9,10], Campylobacter concisus [45] and
Borrelia burgdorferi [46]. It has been shown to bind to
plasminogen and plays a role in the pathogenesis of a variety
of organisms, including Bo. burgdoferi [46], oral streptococci
[47] and Neisseria meningitides [13]. Enolase expressed by Bo.
burgdoferi lacks a signal peptidase cleavage site and cell wall
anchor sequences, but was associated with outer-membrane
vesicles which may be related to plasmin fixing to the
peribacterial environment [46]. Another host binding protein,
lysM domain/M23 peptidase domain protein was identified in all
strains except C1394. A protein with these domains has been
previously identified as a fibronectin-binding protein involved in
T. denticola-associated with periodontal disease [48]. A LysM
domain protein was also identified among proteins secreted
from S. pneumoniae [9]. Further analysis of host binding
proteins such as these may give better insights in to the
pathogenesis of Bcc.
The 38 kDa Oxidoreductase-aldo/ketoreductase (38 kDa, pI
5.8) was identified among the immunogens in both species.
Although this enzyme has not been identified in previous
immunoproteomics studies of other bacterial pathogens, a
member of the aldo/ ketoreductase family (33 kDa) from
Trypanosoma cruzi has been identified as a major immunogen
in alkaline fractions of T. cruzi, generating potent B-cell
responses in mice [49]. Another aldo/ketoreductase has been
associated with uropathogenic E. coli [50]. F0F1 ATP synthase
subunits were immunoreactive in all four strains. The alpha
subunit (55 kDa) of all strains except C1394 was identified as
immunoreactive, while the beta subunit (50kDa) was identified
as immunogenic in C1394. Both subunits were listed as
immunoreactive proteins in a dominant serotype of S. flexineri
[34]. The alpha subunit was one of three proteins found to be
immunoreactive across all sera from 10 patients with Crohn’s
disease when used to probe C. concisus blots [45]. In addition,
the alpha subunit of ATP synthase may also be involved in the
endothelial invasion mechanism of Bartonella hensellae [51].
The F0F1 ATP synthase beta subunit was identified among 18
immunogenic proteins in Brucella abortus [52] and in two
Bordetella pertussis vaccine strains [53,54]. ATP synthase beta
subunit of the periodontitis-associated pathogen
Aggregatibacter acinomycetemcomitans has been shown to
bind to human interleukin-1β and may be associated with the
suppression of local inflammation [55]. The finding that two
subunits of this conserved protein are immunoreactive in Bcc
warrants further investigation as to its role in pathogenesis.
Another immunoreactive protein identified in both B.
cenocepacia strains was Alkyl hydroperoxide reductase
(AhpC). It shows 98% identity with another immunoreactive
protein identified in B. multivorans, hydroperoxide reductase
(Blast-P) [20]. AhpC was down regulated in a persistent isolate
of B. cenocepacia C1394 during murine infection and loss of
this protein was associated with enhanced susceptibility to
oxidative stress [56]. More recently Zlosnik et al. showed that
AhpC was strongly overexpressed in a non-mucoid B.
cenocepacia isolate during chronic infection and was
suggested to play a role in resistance towards killing by
phagocytes [57]. Furthermore, AhpC was an immunoreactive
surface protein in another member of genus Burkholderia, B.
thailandensis [14]. Another protein that was identified in both
species as immunogenic in three of the strains was the
dipeptide transporter ATP-binding subunit. This has also been
identified as immunoreactive in S. pneumoniae and also
identified by expression library immunisation in B. mallei,
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another related Burkholderia respiratory pathogen associated
with glanders in horses [9,58].
Metabolic enzymes are often identified as immunoreactive in
bacterial pathogens and may indicate a role in pathogenesis
[15]. Citrate synthase was identified as immunogenic in both B.
multivorans strains. Mutations in a putative citrate synthase
gene in B. cenocepacia (BCAS207) resulted in reductions in
biofilm formation and partial deficient virulence [59].
Furthermore, inosine monophosphate dehydrogenase (IMPDH)
was reproducibly identified in B. cenocepacia strain C1394
only. IMPDH plays a role in virulence in the swine pathogen,
Streptococcus suis, type 2; deletion mutants of this gene
cannot form hyaluronic acid capsule and have a reduced rate
of invasion [60]. Its potential role in virulence of B. cenocepacia
remains to be elucidated.
Overall, several immunoreactive proteins have been
identified in this study, which were previously identified as
virulence proteins in other pathogens. Although many of these
were common to both clinically relevant species, the number
common to all four strains examined was minimal, highlighting
the diversity across Bcc strains, which is a hallmark of Bcc.
These immunoreactive proteins which were also shown to be
involved in pathogenesis of other organisms warrant further
investigation in order to elucidate the mechanisms of
pathogenesis of this highly virulent opportunistic pathogen. The
potential for these immunogenic proteins to be vaccine
antigens remains unexplored to date. Antigens which were
common to both B. multivorans and B. cenocepacia in addition
to other Bcc species would be advantageous in terms of their
potential to protect people with CF from a range of species with
the Bcc. Furthermore, prior to development of any vaccine
antigen any potential cross reactivity with commensal bacteria
would need to be ruled out. Given the fact that Bcc has an
intracellular component to its lifestyle, in addition to
extracellular adhesion, the cellular responses of any antigens
would need to be explored in addition to the humoral response
in developing protective vaccines against this organism.
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